Table 1.
Characteristics of 30 patients with 33 lesions.
| Characteristics | Number or value |
|---|---|
| Gender | |
| Male/female | 17/13 |
| Age (years) | |
| Median (range) | 52.5 (19–81) |
| Primary diagnosis | |
| WHO grade II/III/IV | 6/9/15 |
| Most recent histological diagnosis | |
| WHO grade II/III/IV | 2/10/18 |
| Performance status | |
| 0/1/2/3/4 | 9/10/5/4/2 |
| Tumor location | |
| F/P/T/O/CC/BG/CB | 9/1/5/3/6/5/4 |
| Tumor morphological type | |
| Diffuse/other | 11/22 |
| Contrast-enhancing tumor volume (cc) | |
| Median (range) | 3.2 (0–36.1) |
| PTV volume (cc) | |
| Median (range) | 9.0 (1.0–140.0) |
| Target delineation | |
| Method A/B | 16/17 |
| Dose per fraction (Gy) | |
| 4.5/5/6/7 | 1/3/8/21 |
| Concurrent chemotherapy with SRT | |
| None/TMZ/ICE/Others | 17/4/4/5 |
BG, basal ganglion; CB, cerebellum; CC, corpus callosum; F, frontal lobe; ICE, ifosfamide, carboplatin, and etoposide; O, occipital lobe; P, parietal lobe; SRT stereotactic radiotherapy; T, temporal lobe; TMZ, temozolomide; WHO, World Health Organization.